Xilio Therapeutics is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, that uses proprietary technology to develop tumor-selective immunotherapies with the potential to cure cancer. The company's technology maximizes the potency of immuno-oncology therapies while minimizing peripheral side effects, making them applicable to all cancer types. Xilio Therapeutics is building a broad pipeline of engineered antibodies, cytokines, and chemokines to provide new treatment options for cancer patients. The company's name, Xilio, is derived from the Latin term Ex Nihilo, meaning creation or big-bang, reflecting its mission to unleash the power of the immune system selectively at the site of the tumor.